Allakos Inc. (NASDAQ: ALLK)
$0.86
+0.0028 ( +0.33% ) 510.1K
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Market Data
Open
$0.86
Previous close
$0.86
Volume
510.1K
Market cap
$76.41M
Day range
$0.85 - $0.91
52 week range
$0.72 - $5.64
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 29, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
8-k | 8K-related | 11 | May 28, 2024 |
8-k | 8K-related | 12 | May 28, 2024 |
8-k | 8K-related | 12 | May 09, 2024 |
10-q | Quarterly Reports | 65 | May 09, 2024 |
def | Proxies and info statements | 10 | Apr 23, 2024 |
8-k | 8K-related | 11 | Apr 23, 2024 |
ars | Annual reports | 1 | Apr 23, 2024 |
10-k | Annual reports | 84 | Mar 14, 2024 |